Parminder P. Singh, MD, FACC
Consultative Cardiology, Interventional Cardiology, Peripheral Intervention, Carotid Angioplasty and Stenting and Pacemaker Implantation
Dr. Singh is board certified in Interventional Cardiology, Cardiovascular Diseases, Internal Medicine and Geriatrics. He earned his medical degree from the Government Medical College in Amritsar, India. He completed his internal medicine residency at Wayne State University – Detroit Medical Center, Detroit, Michigan. Dr. Singh completed a fellowship in Geriatrics at the University of Michigan, Ann Arbor, Michigan. He then attended Wayne State University-Detroit Medical Center for his fellowship in Cardiovascular Diseases. After several years in private practice in Bangor, Maine he completed an interventional cardiology fellowship at the Albany Medical Center and Heart Institute. Dr. Singh is board certified in echocardiography by the American Board of Echocardiography and certified in nuclear cardiology by the Certification Board of Nuclear Cardiology.
- Dr Singh Graduated among the top 10% percentile in the country during the Cardiovascular subspecialty examination conducted by the American Board of Internal Medicine in 2002.
- He also Secured 90th percentile in the American Board of Internal Medicine certification examination,1998.
- Special Recognition for an outstanding medical student teacher by the Dean of the Wayne State University School of Medicine, one of the largest Medical Schools in the USA.
- DIABETES AND CARDIOVASCULAR DISEASES, SINGH P, KAUR J, SOWERS JR, AMERICAN JOURNAL OF THERPEUTICS 2002: NOV-DEC; 9(6) 510-5 – This was an extensive review article on the impact of Diabetes Mellitus on the Cardiovascular diseases. Due to increasing obesity in the US, the incidence of Diabetes Mellitus continues to increase leading on to increased cardiovascular morbidity and mortality. Both in Men and women, the leading cause of mortality is cardiovascular diseases and its implications discussed in this review article.
- CYTOMEGALOVIRUS –INDUCED GINGIVAL HYPERPLASIA, KAUR J, SINGH P, LEVINE D, CLINICAL INFECTIOUS DISEASE 2003 AUG 15; 37(4): e 44-6
- MULTIPLE MYELOMA IN THE LIVER, KAUR J, TURNER J, SINGH P, AL-KATIB, AYAD, AMERICAN JOURNAL OF HEMATOLOGY, VOL 65 ISSUE 4, DECEMBER 2000
- COCAINE INDUCED TORSADES DE POINTES IN IDIOPATHIC LONG QT SYNDROME, SINGH N, SINGH P, KHAN IA, AMERICAN JOURNAL OF THERAPEUTICS JUL-AUG 2001; 8(4) 299-302
- TUBERCULAR LIVER ABCESS, SINGH P, ARORA R, MAHAJAN DS, BATRA KS, SHARMA OP, INDIAN JOURNAL OF CLINICAL PRACTICE, FEB1995, VOL 5
- DRUG INDUCED PANCYTOPENIA, KAUR J, SINGH P, LaCHANT N, AMERICAL COLLEGE OF PHYSICIANS, MICHIGAN CHAPTER, 1999
- PROSTHETIC VALVE ENDOCARDITIS DUE TO S.MALTOPHILIA, SINGH P, BROWN PATRICIA, AMERICAN COLLEGE OF PHYSICIANS, MICHIGAN CHAPTER, 1997
- PERSISTENTLY NORMAL GLYCATED HEMOGLOBIN IN POORLY, CONTROLLED TYPE 1 DIABETES MELLITUS, KAUR J, KLEEREKOPER M, SINGH P, MAHAKALA A, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, 2002, ABSTRACT AND POSTER PRESENTATION
- A SIX MONTH COMPARATIVE EVALUATION OF AMLODIPINE WHICH IS (NORVASC- TOP 10 SELLING DRUG IN THE WORLD) VERSUS ENALAPRIL IN MILD TO MODERATE HYPERTENSION – ACCEPTED AND PUBLISHED AS A THESIS IN THE MD DEGREE). Parminder Singh, OP Sharma.-1994 – This was a 6 months study conducted in 1994 to compare the effect of Amlodipine well known as NORVASC from Pfizer (Among the top 5 selling medication in the World –US Sales 2.2 Billion dollars in 2003 as per IMS, a healthcare information firm—Forbes.com) comparing it with Enalapril, another drug given for hypertension (high Blood Pressure).This study revealed that Amlodipine was better than Enalapril in mild to moderate Hypertension in Indian ethnic population.
- BRIDGING STUDY : Principal Cardiology fellow Investigator for Phase 2 Multicenter-Randomized Trail Comparing outpatient Tinzaprin versus inpatient Intravenous Heparin who are getting long term warfarin therapy for invasive or surgical procedure at Harper University Hospital ( 3rd largest center out of 28 in the US).
Dr. Singh was involved in the recruitment for several patients for these trials while working in private practice in Bangor ,Maine as well as during his general Cardiology and Interventional Cardiology fellow ship
- CHF- RESTORE-US ( OUT PATIENT STUDY) EDTRONIC – BI VENTRICULAR PACEMAKER IMPLANTATION – was a 12 month study in patients who are older than 18 years of age and have been diagnosed with Heart failure for at least one month prior to enrollment. They need to have New York Heart Association Class III or IV dyspnea (Cannot walk more than 2 blocks and are short of breath at rest). The QRS is greater than or equal to 130 ms and Ejection fraction less than or equal to 35%. These patients are symptomatic while receiving optimal drug therapy for heart failure and are expected to survive 12 months.
- PERISCOPE – ACTOS VERSUS AMARYL ON CAD IN PATIENTS WITH TYPE 2 DIABETES MELLITUS – It was a trial comparing the effect of two Diabetes Medication Pioglitazone HCL (ACTOS) vs. Glimepiride (AMARYL) on a change in atheroma (fatty plaque) in the arteries of the heart. Changes in the heart are assessed using intravascular ultrasound (IVUS) imaging. This is being conducted in women and men between the age of 35 to 85 years who are TYPE II Diabetic and have evidence of angiographic coronary artery disease and presents for cardiac catheterization with and without intervention. It is a 18 month study sponsored by Takeda Pharmaceuticals North America,Inc.
- ACUITY ( ACUTE CATHETERIZATION AND URGENT INTERVENTION TRIAGE STRATEGY)
- A MULTICENTER STUDY IN PATIENTS WITH UNSTABLE ANGINA OR NON-ST ELEVATION MYOCARDIAL INFARCTION – It was one of the largest study which is being performed in patients with Acute coronary syndrome undergoing invasive strategy.The primary endpoints include the composite of death, myocardial infarction, unplanned revascularization for ischemia and major bleeding at 30 days.Patients are older than 18 years of age and have evidence of unstable angina and NSTEMI ( heart attack) who have ECG changes or abnormal cardiac enzymes and history of heart attack, coronary artery disease or CABG in the past or patient is older than 65 with aspirin use in last 7 days and 2 or more episode of angina in last 24 hours along with 3 more risk factors including Hypertension ( high Blood pressure), High cholesterol, family Hx of Diabetes mellitus or current smoker. The ACUITY trial compares the effect of two blood thinning medication as Enoxaprin and Bivalirudin in patients with acute coronary syndrome .
- TITAN –TIMI 34 ST ELEVATION MYOCARDIAL INFARCTION Time to Integrilin therapy in acute Myocardial infarction-timi 34. – The main objective is the impact of integrilin ( Eptifibatide ) in the Emergency room versus the cardiac catheterization laboratory on the Epicardial flow and tissue level perfusion in the setting of primary PCI for STEMI. It is a phase IV ,randomized ,open label multicenter trial to see the Efficacy of earlier initiation of integrilin. There are 36 sites in the country. With NECA, being one of them. Patients have chest pain of greater or equal to 20 minutes and less than 6 hours and the ECG shows ST elevation greater Or equal than 1 mm in the limb leads and greater or equal than 2 mm in the Precordial leads.
- CONGESTIVE HEART FAILURE—EVEREST TOLVAPTAN Patients are Hospitalized for chronic heart failure and maximized on optimal Therapy. It is a phase III trial (study drug given to large number of people to confirm its effectiveness, monitor side effects ) which is randomized, double-blind ,placebo control safety efficacy study which compares the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure.Patients need to have ejection fraction less than 40% and NYHA class III or IV symptoms at the time of hospitalization.
- BRIDGING STUDY – Principal Cardiology fellow investigator in a Phase II, Multicenter, Randomized,Open-Label Prospective Study to Evaluate Tinzaprin versus unfractionated heparin in subjects who were receiving long term warfarin therapy for an invasive or surgical procedure. I actively reviewed patient charts and recruited patients and did all the follow up visits. This was done at Wayne State University School of Medicine/Detroit Medical Center and Harper University Hospital (3rd largest center out of 28 in the US). Total 82 patients recruited in the USA and study is re-launched in Canadian Centers to meet a target of 375 patients due to purchase of Dupont by Bristol-Myers Squibb.
- A six month comparative evaluation of Amlodipine ( NORVASC ) to Enalapril in mild to moderate Hypertension was done at Government Medical College, Amritsar, India where this was presented and accepted as a thesis for Doctor of Medicine ( MD ) degree at the GND,University, Amritsar India.